



## **ANALYST COVERAGE OF ADL BIONATUR SOLUTIONS INITIATED BY CHECKPOINT WITH A TARGET PRICE OF EUR 3.20 PER SHARE**

- Potential 12-month upside of 51% relative to current share price of EUR 2.12
- Estimated enterprise value of EUR 160 million compared to current EV of EUR 121 million

**León, Spain, 12 February 2019** - ADL Bionatur Solutions (MAB: ADL), a company specialized in research and development of health products, services and industrial fermentation production, today announced that Checkpoint, a Madrid-based specialist in corporate finance for emerging technology companies, has initiated coverage of ADL.

Checkpoint estimates ADL's enterprise value (EV) at EUR 160 million on the back of a sum of the parts valuation, relative to the current EV of EUR 121 million. This represents a target price of EUR 3.20 per share (using a 13% equity discount rate), providing an upside of 51% relative to the closing price of EUR 2.12 on the Spanish Alternative Market (MAB) on 11 February 2019.

Checkpoint notes that ADL combines an accredited expertise in development and scale-up processes, with probably the lowest fermentation costs in Europe. Therefore, Checkpoint expects ADL's continued growth following the 65 % sales increase in 2018. ADL's long-term contracts with quality clients and stable cost base, provide good visibility for future earnings and led to Checkpoint's forecast of 37 % sales CAGR over the next 5 years.

The CMO division is, according to Checkpoint, the main driver for revenue growth due to its newly built capacity and strong competitive advantages in terms of costs and its qualified scientific team. Additional capacity extension is expected and the growing scale will enhance its relative competitive advantages. Furthermore, ADL continues to develop its proprietary products and technology platforms within the animal health division and the antibiotics division, which includes APIs, animal vaccines and probiotics.

Not included in the evaluation are ADL's proprietary products for human microbiota and the potential increase in revenues derived from the fermenters' capacity optimization.

The complete Checkpoint report is available at <https://adlbionatur.com/wp-content/uploads/2019/02/ADLBionatur-Initiation-of-Coverage-11-Feb-2019--CheckPoint-1.pdf>

### **About ADL Bionatur Solutions**

ADL Bionatur Solutions (MAB: ADL) is a company specialized in biopharma manufacturing plus research and development targeting the human microbiome and the animal health sector. The Company, that owns the largest fermentation production plant in Southern Europe, carries out high value-added product development, scale-up and production for third parties. International healthcare companies as well as first-in-class academic and industrial laboratories mainly from Europe and the US are part of ADL's customer base. The biopharma manufacturing business is complemented by a research and development division, which creates a proprietary product pipeline in animal and human health. ADL is listed on the MAB, Spain's Alternative Stock Market



(ISIN ES0184980003) and its major shareholder is the investment fund Black Toro Capital holding 73%. More information is available at [www.adlbionatur.com](http://www.adlbionatur.com)

**For more Information please contact:**

**ADL Bionatur Solutions**

Blanca San Román

IRO and Communications

Email: [ir@adlbionatur.com](mailto:ir@adlbionatur.com)

**International Media & Investor Relations**

MC Services

Raimund Gabriel

Tel.: +49 89 21022880

Email: [ADLbionatursolutions@mc-services.eu](mailto:ADLbionatursolutions@mc-services.eu)